PMV Pharmaceuticals, Inc.
PMVPNASDAQHealthcare● Active
$1.09
$-0.03(-2.68%)
Market Cap$58131625
P/E Ratio—
52W High$1.88
52W Low$0.964
PMV Pharmaceuticals, Inc. (PMVP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PMVP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.34
Est. -$0.41 · +17.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
PMVP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.43 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.41 | -$0.34 | +17.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 6, 2026 | -$0.40 | -$0.34 | +15.0% | — | — | — |
| — Q4 FY2025 | Nov 12, 2025 | -$0.40 | -$0.40 | +0.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.39 | -$0.41 | -5.1% | — | — | — |
| ▲ Q2 FY2025 | May 9, 2025 | -$0.37 | -$0.34 | +8.1% | — | — | — |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.38 | -$0.45 | -18.4% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.35 | -$0.37 | -5.7% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.43
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.34
EPS Est.
-$0.41
EPS Surpr.
+17.1%
Revenue
—
Q1 FY2026
Mar 6, 2026Beat
EPS Actual
-$0.34
EPS Est.
-$0.40
EPS Surpr.
+15.0%
Revenue
—
Q4 FY2025
Nov 12, 2025
EPS Actual
-$0.40
EPS Est.
-$0.40
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.39
EPS Surpr.
-5.1%
Revenue
—
Q2 FY2025
May 9, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.37
EPS Surpr.
+8.1%
Revenue
—
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.38
EPS Surpr.
-18.4%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.37
EPS Est.
-$0.35
EPS Surpr.
-5.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q2 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q1 FY2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q4 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2026 | $-0.41 | $-0.37 | $-0.32 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +17.1% | $1.39 | $1.42 | +2.16% |
| ▲ Q1 FY2026 | Mar 6, 2026 | +15.0% | $1.53 | $1.64 | +7.19% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +0.0% | $1.33 | $1.42 | +6.77% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -5.1% | $1.52 | $1.45 | -4.61% |
| ▲ Q2 FY2025 | May 9, 2025 | +8.1% | $0.88 | $0.88 | -0.12% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -18.4% | $1.37 | $1.32 | -3.65% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -5.7% | $1.66 | $1.78 | +7.23% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +94.1% | $1.46 | $1.46 | +0.00% |
Q2 FY2026+2.16%
Report Date
May 12, 2026
EPS Beat/Miss
+17.1%
Price Before
$1.39
Price After
$1.42
Q1 FY2026+7.19%
Report Date
Mar 6, 2026
EPS Beat/Miss
+15.0%
Price Before
$1.53
Price After
$1.64
Q4 FY2025+6.77%
Report Date
Nov 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.33
Price After
$1.42
Q3 FY2025-4.61%
Report Date
Aug 7, 2025
EPS Beat/Miss
-5.1%
Price Before
$1.52
Price After
$1.45
Q2 FY2025-0.12%
Report Date
May 9, 2025
EPS Beat/Miss
+8.1%
Price Before
$0.88
Price After
$0.88
Q1 FY2025-3.65%
Report Date
Mar 3, 2025
EPS Beat/Miss
-18.4%
Price Before
$1.37
Price After
$1.32
Q4 FY2024+7.23%
Report Date
Nov 7, 2024
EPS Beat/Miss
-5.7%
Price Before
$1.66
Price After
$1.78
Q3 FY2024+0.00%
Report Date
Aug 8, 2024
EPS Beat/Miss
+94.1%
Price Before
$1.46
Price After
$1.46
Avg Beat Reaction+3.20%
Avg Miss Reaction-0.34%
Beat Rate5 / 8 quarters
Largest Move+7.23% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PMVP ends December
PMV Pharmaceuticals, Inc. (PMVP) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.34 — beating the analyst consensus of $-0.41 by +17.1%. PMVP has beaten EPS estimates for 3 consecutive quarters. The next PMVP earnings date is expected around September 1, 2026.
Each quarter, investors track PMVP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PMVP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PMVP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PMVP earnings · 5 questionsPMV Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. PMVP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PMVP historically reports after market close (AMC).
PMVP earnings datewhen is PMVP earningsPMVP next earnings datewhen does PMVP report earningsPMVP earnings calendar
▸ Source: FMP · PMV Pharmaceuticals, Inc. SEC filings · US GAAP · PMV Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026